메뉴 건너뛰기




Volumn 37, Issue 2, 2011, Pages 143-150

Second-line chemotherapy for small-Cell Lung Cancer (SCLC)

Author keywords

Chemotherapy; Refractory; Relapsed; Second line; Sensitive; Small cell lung cancer

Indexed keywords

AMBAMUSTINE; AMRUBICIN; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEHYDRODIDEMNIN B; DOXORUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LURTOTECAN; NIMUSTINE; PACLITAXEL; PEMETREXED; PICOPLATIN; SORAFENIB; TENIPOSIDE; TIPIFARNIB; TOPOTECAN; VINCRISTINE;

EID: 79151482317     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.05.004     Document Type: Review
Times cited : (42)

References (95)
  • 1
    • 33750603100 scopus 로고    scopus 로고
    • Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
    • Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
    • (2006) J Clin Oncol , vol.24 , pp. 4539-4544
    • Govindan, R.1    Page, N.2    Morgensztern, D.3
  • 2
    • 0034896786 scopus 로고    scopus 로고
    • Treatment of relapsed small cell lung cancer
    • Postmus P.E., Smit E.F. Treatment of relapsed small cell lung cancer. Semin Oncol 2001, 28:48-52.
    • (2001) Semin Oncol , vol.28 , pp. 48-52
    • Postmus, P.E.1    Smit, E.F.2
  • 3
    • 0023677771 scopus 로고
    • Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy
    • Giaccone G., Donadio M., Bonardi G., et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988, 6:1264-1270.
    • (1988) J Clin Oncol , vol.6 , pp. 1264-1270
    • Giaccone, G.1    Donadio, M.2    Bonardi, G.3
  • 4
    • 0031157599 scopus 로고    scopus 로고
    • Second-line chemotherapy for relapsed small cell lung cancer
    • Ebi N., Kubota K., Nishiwaki Y., et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997, 27:166-169.
    • (1997) Jpn J Clin Oncol , vol.27 , pp. 166-169
    • Ebi, N.1    Kubota, K.2    Nishiwaki, Y.3
  • 5
    • 33645799480 scopus 로고    scopus 로고
    • Small cell lung cancer
    • Rosti G., Bevilacqua G., Bidoli P., et al. Small cell lung cancer. Ann Oncol 2006, 17(SUPPL 2):ii5-ii10.
    • (2006) Ann Oncol , vol.17 , Issue.SUPPL 2
    • Rosti, G.1    Bevilacqua, G.2    Bidoli, P.3
  • 6
    • 0023551782 scopus 로고
    • Reinduction chemotherapy in small cell lung cancer
    • Giaccone G., Ferrati P., Donadio M., et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987, 23:1697-1699.
    • (1987) Eur J Cancer Clin Oncol , vol.23 , pp. 1697-1699
    • Giaccone, G.1    Ferrati, P.2    Donadio, M.3
  • 7
    • 0023519996 scopus 로고
    • Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy
    • Postmus P.E., Berendsen H.H., van Zandwijk N., et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987, 23:1409-1411.
    • (1987) Eur J Cancer Clin Oncol , vol.23 , pp. 1409-1411
    • Postmus, P.E.1    Berendsen, H.H.2    van Zandwijk, N.3
  • 8
    • 0037330778 scopus 로고    scopus 로고
    • Recurrent small cell lung cancer: update
    • Glisson B.S. Recurrent small cell lung cancer: update. Semin Oncol 2003, 30:72-78.
    • (2003) Semin Oncol , vol.30 , pp. 72-78
    • Glisson, B.S.1
  • 9
    • 16644400607 scopus 로고    scopus 로고
    • Topotecan in the treatment of recurrent small cell lung cancer: an update
    • Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist 2004, 9(Suppl 6):4-13.
    • (2004) Oncologist , vol.9 , Issue.SUPPL 6 , pp. 4-13
    • Ardizzoni, A.1
  • 10
    • 34247197121 scopus 로고    scopus 로고
    • Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301
    • Onoda S., Masuda N., Seto T., et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: thoracic oncology research group study 0301. J Clin Oncol 2006, 24:5448-5453.
    • (2006) J Clin Oncol , vol.24 , pp. 5448-5453
    • Onoda, S.1    Masuda, N.2    Seto, T.3
  • 11
    • 56749131841 scopus 로고    scopus 로고
    • Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402
    • Inoue A., Sugawara S., Yamazaki K., et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol 2008, 26:5401-5406.
    • (2008) J Clin Oncol , vol.26 , pp. 5401-5406
    • Inoue, A.1    Sugawara, S.2    Yamazaki, K.3
  • 12
    • 0021355382 scopus 로고
    • VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer
    • Evans W.K., Feld R., Osoba D., et al. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 1984, 53:1461-1466.
    • (1984) Cancer , vol.53 , pp. 1461-1466
    • Evans, W.K.1    Feld, R.2    Osoba, D.3
  • 13
    • 0022610637 scopus 로고
    • Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern cancer study group trial
    • Wolff S.N., Birch R., Sarma P., Greco F.A. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern cancer study group trial. Cancer Treat Rep 1986, 70:583-587.
    • (1986) Cancer Treat Rep , vol.70 , pp. 583-587
    • Wolff, S.N.1    Birch, R.2    Sarma, P.3    Greco, F.A.4
  • 14
    • 0037050354 scopus 로고    scopus 로고
    • Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
    • Noda K., Nishiwaki Y., Kawahara M., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
    • (2002) N Engl J Med , vol.346 , pp. 85-91
    • Noda, K.1    Nishiwaki, Y.2    Kawahara, M.3
  • 15
    • 33646447066 scopus 로고    scopus 로고
    • Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    • Hanna N., Bunn P.A., Langer C., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
    • (2006) J Clin Oncol , vol.24 , pp. 2038-2043
    • Hanna, N.1    Bunn, P.A.2    Langer, C.3
  • 16
    • 66349102227 scopus 로고    scopus 로고
    • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124
    • Lara P.N., Natale R., Crowley J., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530-2535.
    • (2009) J Clin Oncol , vol.27 , pp. 2530-2535
    • Lara, P.N.1    Natale, R.2    Crowley, J.3
  • 17
    • 0026680292 scopus 로고
    • CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
    • Masuda N., Fukuoka M., Kusunoki Y., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992, 10:1225-1229.
    • (1992) J Clin Oncol , vol.10 , pp. 1225-1229
    • Masuda, N.1    Fukuoka, M.2    Kusunoki, Y.3
  • 18
    • 67449163727 scopus 로고    scopus 로고
    • A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer
    • Pallis A.G., Agelidou A., Agelaki S., et al. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung cancer 2009, 65:187-191.
    • (2009) Lung cancer , vol.65 , pp. 187-191
    • Pallis, A.G.1    Agelidou, A.2    Agelaki, S.3
  • 19
    • 0031470891 scopus 로고    scopus 로고
    • Anti-tumor efficacy of paclitaxel against human lung cancer xenografts
    • Yamori T., Sato S., Chikazawa H., Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 1997, 88:1205-1210.
    • (1997) Jpn J Cancer Res , vol.88 , pp. 1205-1210
    • Yamori, T.1    Sato, S.2    Chikazawa, H.3    Kadota, T.4
  • 20
    • 0029071979 scopus 로고
    • Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern cooperative oncology group study
    • Ettinger D.S., Finkelstein D.M., Sarma R.P., Johnson D.H. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern cooperative oncology group study. J Clin Oncol 1995, 13:1430-1435.
    • (1995) J Clin Oncol , vol.13 , pp. 1430-1435
    • Ettinger, D.S.1    Finkelstein, D.M.2    Sarma, R.P.3    Johnson, D.H.4
  • 21
    • 0031985696 scopus 로고    scopus 로고
    • A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
    • Smit E.F., Fokkema E., Biesma B., et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998, 77:347-351.
    • (1998) Br J Cancer , vol.77 , pp. 347-351
    • Smit, E.F.1    Fokkema, E.2    Biesma, B.3
  • 22
    • 10744222532 scopus 로고    scopus 로고
    • Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
    • Hoang T., Kim K., Jaslowski A., et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung cancer 2003, 42:97-102.
    • (2003) Lung cancer , vol.42 , pp. 97-102
    • Hoang, T.1    Kim, K.2    Jaslowski, A.3
  • 23
    • 57649094926 scopus 로고    scopus 로고
    • Studies of pemetrexed, gemcitabine, alone, in combinations, in human lung cancer models
    • Chan D.C., Chen V.J., Zhang Z., et al. Studies of pemetrexed, gemcitabine, alone, in combinations, in human lung cancer models. ASCO Meeting Abs 2006, 24:17114.
    • (2006) ASCO Meeting Abs , vol.24 , pp. 17114
    • Chan, D.C.1    Chen, V.J.2    Zhang, Z.3
  • 24
    • 61549083739 scopus 로고    scopus 로고
    • Pemetrexed in second line and beyond small cell lung cancer: a Hoosier oncology group phase II study
    • Jalal S., Ansari R., Govindan R., et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier oncology group phase II study. J Thorac Oncol 2009, 4:93-96.
    • (2009) J Thorac Oncol , vol.4 , pp. 93-96
    • Jalal, S.1    Ansari, R.2    Govindan, R.3
  • 25
    • 57649092721 scopus 로고    scopus 로고
    • A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer
    • Gronberg B.H., Bremnes R.M., Aasebo U., et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung cancer 2009, 63:88-93.
    • (2009) Lung cancer , vol.63 , pp. 88-93
    • Gronberg, B.H.1    Bremnes, R.M.2    Aasebo, U.3
  • 26
    • 70350435454 scopus 로고    scopus 로고
    • Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer
    • Socinski M.A., Smit E.F., Lorigan P., et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009, 27:4787-4792.
    • (2009) J Clin Oncol , vol.27 , pp. 4787-4792
    • Socinski, M.A.1    Smit, E.F.2    Lorigan, P.3
  • 27
    • 65349157711 scopus 로고    scopus 로고
    • Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer
    • Eckardt J.R., Bentsion D.L., Lipatov O.N., et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009, 27:2046-2051.
    • (2009) J Clin Oncol , vol.27 , pp. 2046-2051
    • Eckardt, J.R.1    Bentsion, D.L.2    Lipatov, O.N.3
  • 28
    • 0026574296 scopus 로고
    • Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC lung cancer cooperative group
    • Planting A.S., Splinter T.A., Ardizzoni A., et al. Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC lung cancer cooperative group. Cancer Chemother Pharmacol 1992, 29:409-411.
    • (1992) Cancer Chemother Pharmacol , vol.29 , pp. 409-411
    • Planting, A.S.1    Splinter, T.A.2    Ardizzoni, A.3
  • 29
    • 0034122631 scopus 로고    scopus 로고
    • Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study
    • Ardizzoni A., Antonelli G., Ricci S., et al. Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. Am J Clin Oncol 2000, 23:22-25.
    • (2000) Am J Clin Oncol , vol.23 , pp. 22-25
    • Ardizzoni, A.1    Antonelli, G.2    Ricci, S.3
  • 30
    • 0034066518 scopus 로고    scopus 로고
    • Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC early clinical studies group (ECSG)
    • Sessa C., Wanders J., Roelvink M., et al. Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC early clinical studies group (ECSG). Ann Oncol 2000, 11:207-210.
    • (2000) Ann Oncol , vol.11 , pp. 207-210
    • Sessa, C.1    Wanders, J.2    Roelvink, M.3
  • 31
    • 0033638112 scopus 로고    scopus 로고
    • Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic cooperative oncology group study
    • Samantas E., Kalofonos H., Linardou H., et al. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic cooperative oncology group study. Ann Oncol 2000, 11:1395-1397.
    • (2000) Ann Oncol , vol.11 , pp. 1395-1397
    • Samantas, E.1    Kalofonos, H.2    Linardou, H.3
  • 32
    • 33845991547 scopus 로고    scopus 로고
    • Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients
    • Schmittel A., Knodler M., Hortig P., et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung cancer 2007, 55:109-113.
    • (2007) Lung cancer , vol.55 , pp. 109-113
    • Schmittel, A.1    Knodler, M.2    Hortig, P.3
  • 33
    • 61749103952 scopus 로고    scopus 로고
    • Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer
    • Eisen T., Thatcher N., Leyvraz S., et al. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung cancer 2009, 64:60-65.
    • (2009) Lung cancer , vol.64 , pp. 60-65
    • Eisen, T.1    Thatcher, N.2    Leyvraz, S.3
  • 34
    • 0021919567 scopus 로고
    • Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer
    • Evans W.K., Osoba D., Feld R., et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985, 3:65-71.
    • (1985) J Clin Oncol , vol.3 , pp. 65-71
    • Evans, W.K.1    Osoba, D.2    Feld, R.3
  • 35
    • 0023912834 scopus 로고
    • Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer
    • Figoli F., Veronesi A., Ardizzoni A., et al. Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. Cancer Invest 1988, 6:1-5.
    • (1988) Cancer Invest , vol.6 , pp. 1-5
    • Figoli, F.1    Veronesi, A.2    Ardizzoni, A.3
  • 36
    • 0025301524 scopus 로고
    • Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer
    • Masuda N., Fukuoka M., Matsui K., et al. Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 1990, 65:2635-2640.
    • (1990) Cancer , vol.65 , pp. 2635-2640
    • Masuda, N.1    Fukuoka, M.2    Matsui, K.3
  • 37
    • 0022453457 scopus 로고
    • Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates
    • Batist G., Carney D.N., Cowan K.H., et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol 1986, 4:982-986.
    • (1986) J Clin Oncol , vol.4 , pp. 982-986
    • Batist, G.1    Carney, D.N.2    Cowan, K.H.3
  • 38
    • 0021868156 scopus 로고
    • Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung
    • Porter L.L., Johnson D.H., Hainsworth J.D., et al. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung. Cancer Treat Rep 1985, 69:479-481.
    • (1985) Cancer Treat Rep , vol.69 , pp. 479-481
    • Porter, L.L.1    Johnson, D.H.2    Hainsworth, J.D.3
  • 39
    • 0036737753 scopus 로고    scopus 로고
    • A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
    • Sculier J.P., Lafitte J.J., Lecomte J., et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002, 13:1454-1459.
    • (2002) Ann Oncol , vol.13 , pp. 1454-1459
    • Sculier, J.P.1    Lafitte, J.J.2    Lecomte, J.3
  • 40
    • 12144285917 scopus 로고    scopus 로고
    • Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer
    • Ando M., Kobayashi K., Yoshimura A., et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung cancer 2004, 44:121-127.
    • (2004) Lung cancer , vol.44 , pp. 121-127
    • Ando, M.1    Kobayashi, K.2    Yoshimura, A.3
  • 41
    • 0036754116 scopus 로고    scopus 로고
    • Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer
    • Naka N., Kawahara M., Okishio K., et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung cancer 2002, 37:319-323.
    • (2002) Lung cancer , vol.37 , pp. 319-323
    • Naka, N.1    Kawahara, M.2    Okishio, K.3
  • 42
    • 0038697970 scopus 로고    scopus 로고
    • Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer
    • Hirose T., Horichi N., Ohmori T., et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung cancer 2003, 40:333-338.
    • (2003) Lung cancer , vol.40 , pp. 333-338
    • Hirose, T.1    Horichi, N.2    Ohmori, T.3
  • 43
    • 0031725727 scopus 로고    scopus 로고
    • Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer
    • Masuda N., Matsui K., Negoro S., et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998, 16:3329-3334.
    • (1998) J Clin Oncol , vol.16 , pp. 3329-3334
    • Masuda, N.1    Matsui, K.2    Negoro, S.3
  • 44
    • 32044459548 scopus 로고    scopus 로고
    • Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    • Schuette W., Nagel S., Juergens S., et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer 2005, 7:133-137.
    • (2005) Clin Lung Cancer , vol.7 , pp. 133-137
    • Schuette, W.1    Nagel, S.2    Juergens, S.3
  • 45
    • 33847304461 scopus 로고    scopus 로고
    • Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902
    • Rocha-Lima C.M., Herndon J.E., Lee M.E., et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and leukemia group B study 39902. Ann Oncol 2007, 18:331-337.
    • (2007) Ann Oncol , vol.18 , pp. 331-337
    • Rocha-Lima, C.M.1    Herndon, J.E.2    Lee, M.E.3
  • 46
    • 4344560978 scopus 로고    scopus 로고
    • Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
    • Goto K., Sekine I., Nishiwaki Y., et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 2004, 91:659-665.
    • (2004) Br J Cancer , vol.91 , pp. 659-665
    • Goto, K.1    Sekine, I.2    Nishiwaki, Y.3
  • 47
    • 55549145233 scopus 로고    scopus 로고
    • Phase II study of weekly cisplatin, etoposide, irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC)
    • Kim Y., Goto K., Nishiwaki Y., et al. Phase II study of weekly cisplatin, etoposide, irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC). ASCO Meeting Abs 2006, 24:7088.
    • (2006) ASCO Meeting Abs , vol.24 , pp. 7088
    • Kim, Y.1    Goto, K.2    Nishiwaki, Y.3
  • 48
    • 0033044211 scopus 로고    scopus 로고
    • Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule
    • Groen H.J., Fokkema E., Biesma B., et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 1999, 17:927-932.
    • (1999) J Clin Oncol , vol.17 , pp. 927-932
    • Groen, H.J.1    Fokkema, E.2    Biesma, B.3
  • 49
    • 0035100918 scopus 로고    scopus 로고
    • Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study
    • Kakolyris S., Mavroudis D., Tsavaris N., et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 2001, 12:193-197.
    • (2001) Ann Oncol , vol.12 , pp. 193-197
    • Kakolyris, S.1    Mavroudis, D.2    Tsavaris, N.3
  • 50
    • 0026500785 scopus 로고
    • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern cancer study group
    • Roth B.J., Johnson D.H., Einhorn L.H., et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern cancer study group. J Clin Oncol 1992, 10:282-291.
    • (1992) J Clin Oncol , vol.10 , pp. 282-291
    • Roth, B.J.1    Johnson, D.H.2    Einhorn, L.H.3
  • 51
    • 0026817415 scopus 로고
    • Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience
    • Postmus P.E., Smit E.F., Berendsen H.H., Haaxma-Reiche H. Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Semin Oncol 1992, 19:17-23.
    • (1992) Semin Oncol , vol.19 , pp. 17-23
    • Postmus, P.E.1    Smit, E.F.2    Berendsen, H.H.3    Haaxma-Reiche, H.4
  • 52
    • 0027324330 scopus 로고
    • Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC lung cancer cooperative group
    • Postmus P.E., Smit E.F., Kirkpatrick A., Splinter T.A. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC lung cancer cooperative group. Eur J Cancer 1993, 29A:204-207.
    • (1993) Eur J Cancer , vol.29 A , pp. 204-207
    • Postmus, P.E.1    Smit, E.F.2    Kirkpatrick, A.3    Splinter, T.A.4
  • 53
    • 0027222990 scopus 로고
    • Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer
    • Falk S.J., Maughan T.S., Laurence V.M., et al. Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer. Clin Oncol (R Coll Radiol) 1993, 5:85-88.
    • (1993) Clin Oncol (R Coll Radiol) , vol.5 , pp. 85-88
    • Falk, S.J.1    Maughan, T.S.2    Laurence, V.M.3
  • 54
    • 0029065069 scopus 로고
    • Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier oncology group trial
    • Faylona E.A., Loehrer P.J., Ansari R., et al. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier oncology group trial. J Clin Oncol 1995, 13:1209-1214.
    • (1995) J Clin Oncol , vol.13 , pp. 1209-1214
    • Faylona, E.A.1    Loehrer, P.J.2    Ansari, R.3
  • 55
    • 0031026188 scopus 로고    scopus 로고
    • Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer
    • Kubota K., Nishiwaki Y., Kakinuma R., et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 1997, 15:292-296.
    • (1997) J Clin Oncol , vol.15 , pp. 292-296
    • Kubota, K.1    Nishiwaki, Y.2    Kakinuma, R.3
  • 56
    • 0043244934 scopus 로고    scopus 로고
    • Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study
    • Ichiki M., Gohara R., Rikimaru T., et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy 2002, 49:200-205.
    • (2002) Chemotherapy , vol.49 , pp. 200-205
    • Ichiki, M.1    Gohara, R.2    Rikimaru, T.3
  • 57
    • 0034094187 scopus 로고    scopus 로고
    • Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier oncology group trial
    • Sonpavde G., Ansari R., Walker P., et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier oncology group trial. Am J Clin Oncol 2000, 23:68-70.
    • (2000) Am J Clin Oncol , vol.23 , pp. 68-70
    • Sonpavde, G.1    Ansari, R.2    Walker, P.3
  • 58
    • 0035155496 scopus 로고    scopus 로고
    • Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer
    • Kosmas C., Tsavaris N.B., Malamos N.A., et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 2001, 19:119-126.
    • (2001) J Clin Oncol , vol.19 , pp. 119-126
    • Kosmas, C.1    Tsavaris, N.B.2    Malamos, N.A.3
  • 59
    • 70350621082 scopus 로고    scopus 로고
    • Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer
    • Isobe K., Kobayashi K., Kosaihira S., et al. Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer. Lung cancer 2009, 66:350-354.
    • (2009) Lung cancer , vol.66 , pp. 350-354
    • Isobe, K.1    Kobayashi, K.2    Kosaihira, S.3
  • 60
    • 33646481051 scopus 로고    scopus 로고
    • Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial
    • Dongiovanni V., Buffoni L., Berruti A., et al. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 2006, 58:203-209.
    • (2006) Cancer Chemother Pharmacol , vol.58 , pp. 203-209
    • Dongiovanni, V.1    Buffoni, L.2    Berruti, A.3
  • 61
    • 33646379346 scopus 로고    scopus 로고
    • Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
    • Leighl N.B., Goss G.D., Lopez P.G., et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung cancer 2006, 52:327-332.
    • (2006) Lung cancer , vol.52 , pp. 327-332
    • Leighl, N.B.1    Goss, G.D.2    Lopez, P.G.3
  • 62
    • 0030913459 scopus 로고    scopus 로고
    • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the lung cancer cooperative group
    • Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the lung cancer cooperative group. J Clin Oncol 1997, 15:2090-2096.
    • (1997) J Clin Oncol , vol.15 , pp. 2090-2096
    • Ardizzoni, A.1    Hansen, H.2    Dombernowsky, P.3
  • 63
    • 0000580721 scopus 로고    scopus 로고
    • Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study
    • Eckardt J., Gralla R., Palmer M.C., et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996, 7(suppl 5):107.
    • (1996) Ann Oncol , vol.7 , Issue.SUPPL 5 , pp. 107
    • Eckardt, J.1    Gralla, R.2    Palmer, M.C.3
  • 64
    • 0002429272 scopus 로고    scopus 로고
    • Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study
    • Depierre A., von Pawel J., Hans K., et al. Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 1997, 18(1):35.
    • (1997) Lung Cancer , vol.18 , Issue.1 , pp. 35
    • Depierre, A.1    von Pawel, J.2    Hans, K.3
  • 65
    • 0038546552 scopus 로고    scopus 로고
    • A phase II study of topotecan in patients with relapsed small-cell lung cancer
    • Takeda K., Negoro S., Sawa T., et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 2003, 4:224-228.
    • (2003) Clin Lung Cancer , vol.4 , pp. 224-228
    • Takeda, K.1    Negoro, S.2    Sawa, T.3
  • 66
    • 0029758947 scopus 로고    scopus 로고
    • Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
    • Perez-Soler R., Glisson B.S., Lee J.S., et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996, 14:2785-2790.
    • (1996) J Clin Oncol , vol.14 , pp. 2785-2790
    • Perez-Soler, R.1    Glisson, B.S.2    Lee, J.S.3
  • 67
    • 0033044111 scopus 로고    scopus 로고
    • Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
    • von Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
    • (1999) J Clin Oncol , vol.17 , pp. 658-667
    • von Pawel, J.1    Schiller, J.H.2    Shepherd, F.A.3
  • 68
    • 0035868768 scopus 로고    scopus 로고
    • Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer
    • von Pawel J., Gatzemeier U., Pujol J.L., et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001, 19:1743-1749.
    • (2001) J Clin Oncol , vol.19 , pp. 1743-1749
    • von Pawel, J.1    Gatzemeier, U.2    Pujol, J.L.3
  • 69
    • 34249941781 scopus 로고    scopus 로고
    • Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
    • Eckardt J.R., von Pawel J., Pujol J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
    • (2007) J Clin Oncol , vol.25 , pp. 2086-2092
    • Eckardt, J.R.1    von Pawel, J.2    Pujol, J.L.3
  • 70
    • 34247218552 scopus 로고    scopus 로고
    • Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
    • O'Brien M.E., Ciuleanu T.E., Tsekov H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447.
    • (2006) J Clin Oncol , vol.24 , pp. 5441-5447
    • O'Brien, M.E.1    Ciuleanu, T.E.2    Tsekov, H.3
  • 71
    • 0024803685 scopus 로고
    • Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts
    • Morisada S., Yanagi Y., Noguchi T., et al. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989, 80:69-76.
    • (1989) Jpn J Cancer Res , vol.80 , pp. 69-76
    • Morisada, S.1    Yanagi, Y.2    Noguchi, T.3
  • 72
    • 0024787057 scopus 로고
    • Toxicological aspects of a novel 9-aminoanthracycline, SM-5887
    • Morisada S., Yanagi Y., Kashiwazaki Y., Fukui M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 1989, 80:77-82.
    • (1989) Jpn J Cancer Res , vol.80 , pp. 77-82
    • Morisada, S.1    Yanagi, Y.2    Kashiwazaki, Y.3    Fukui, M.4
  • 73
    • 0030707665 scopus 로고    scopus 로고
    • Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin
    • Suzuki T., Minamide S., Iwasaki T., et al. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 1997, 15:219-225.
    • (1997) Invest New Drugs , vol.15 , pp. 219-225
    • Suzuki, T.1    Minamide, S.2    Iwasaki, T.3
  • 74
    • 0031758232 scopus 로고    scopus 로고
    • Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs
    • Noda T., Watanabe T., Kohda A., et al. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 1998, 16:121-128.
    • (1998) Invest New Drugs , vol.16 , pp. 121-128
    • Noda, T.1    Watanabe, T.2    Kohda, A.3
  • 75
    • 0031786266 scopus 로고    scopus 로고
    • Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells
    • Yamaoka T., Hanada M., Ichii S., et al. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998, 89:1067-1073.
    • (1998) Jpn J Cancer Res , vol.89 , pp. 1067-1073
    • Yamaoka, T.1    Hanada, M.2    Ichii, S.3
  • 76
    • 0008934675 scopus 로고
    • Phase I-II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in patients with advanced non-small-cell lung cancer
    • Negoro S., Fukuoka M., Nakamura S., Ikegami H., Sugiura T., Ariyoshi Y. Phase I-II study of amrubicin (SM-5887), a novel 9-aminoanthracycline, by iv administration for 3 consecutive days in patients with advanced non-small-cell lung cancer. ASCO Meeting Abs 1995, 14:361.
    • (1995) ASCO Meeting Abs , vol.14 , pp. 361
    • Negoro, S.1    Fukuoka, M.2    Nakamura, S.3    Ikegami, H.4    Sugiura, T.5    Ariyoshi, Y.6
  • 77
    • 34248670669 scopus 로고    scopus 로고
    • Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan thoracic oncology group (WJTOG) study
    • Yana T., Negoro S., Takada M., et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan thoracic oncology group (WJTOG) study. Invest New Drugs 2007, 25:253-258.
    • (2007) Invest New Drugs , vol.25 , pp. 253-258
    • Yana, T.1    Negoro, S.2    Takada, M.3
  • 78
    • 33644838068 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer
    • Okamoto I., Hamada A., Matsunaga Y., et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 2006, 57:282-288.
    • (2006) Cancer Chemother Pharmacol , vol.57 , pp. 282-288
    • Okamoto, I.1    Hamada, A.2    Matsunaga, Y.3
  • 79
    • 34548400284 scopus 로고    scopus 로고
    • Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer
    • Igawa S., Yamamoto N., Ueda S., et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007, 2:741-744.
    • (2007) J Thorac Oncol , vol.2 , pp. 741-744
    • Igawa, S.1    Yamamoto, N.2    Ueda, S.3
  • 80
    • 33751076477 scopus 로고    scopus 로고
    • PhaseII trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)
    • Kato T., Nokihara H., Ohe Y., et al. PhaseII trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). ASCO Meeting Abstracts 2006, 24:7061.
    • (2006) ASCO Meeting Abstracts , vol.24 , pp. 7061
    • Kato, T.1    Nokihara, H.2    Ohe, Y.3
  • 81
    • 77953357859 scopus 로고    scopus 로고
    • A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
    • Kaira K., Sunaga N., Tomizawa Y., et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 2010, 69:99-104.
    • (2010) Lung Cancer , vol.69 , pp. 99-104
    • Kaira, K.1    Sunaga, N.2    Tomizawa, Y.3
  • 82
    • 77956396425 scopus 로고    scopus 로고
    • Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer
    • Ettinger D.S., Jotte R., Lorigan P., et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010, 28:2098-2603.
    • (2010) J Clin Oncol , vol.28 , pp. 2098-2603
    • Ettinger, D.S.1    Jotte, R.2    Lorigan, P.3
  • 83
    • 70349705004 scopus 로고    scopus 로고
    • Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
    • Jotte R., Conkling P., Reynolds C., et al. Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy. ASCO Meeting Abs 2009, 27:8028.
    • (2009) ASCO Meeting Abs , vol.27 , pp. 8028
    • Jotte, R.1    Conkling, P.2    Reynolds, C.3
  • 84
    • 9144230676 scopus 로고    scopus 로고
    • Phase II study of imatinib in patients with small cell lung cancer
    • Johnson B.E., Fischer T., Fischer B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9:5880-5887.
    • (2003) Clin Cancer Res , vol.9 , pp. 5880-5887
    • Johnson, B.E.1    Fischer, T.2    Fischer, B.3
  • 85
    • 27744567206 scopus 로고    scopus 로고
    • A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
    • Dy G.K., Miller A.A., Mandrekar S.J., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16:1811-1816.
    • (2005) Ann Oncol , vol.16 , pp. 1811-1816
    • Dy, G.K.1    Miller, A.A.2    Mandrekar, S.J.3
  • 86
    • 18044381919 scopus 로고    scopus 로고
    • Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial
    • Krug L.M., Crapanzano J.P., Azzoli C.G., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005, 103:2128-2131.
    • (2005) Cancer , vol.103 , pp. 2128-2131
    • Krug, L.M.1    Crapanzano, J.P.2    Azzoli, C.G.3
  • 87
    • 0344089284 scopus 로고    scopus 로고
    • Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens
    • Burger H., den Bakker M.A., Stoter G., et al. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 2003, 39:793-799.
    • (2003) Eur J Cancer , vol.39 , pp. 793-799
    • Burger, H.1    den Bakker, M.A.2    Stoter, G.3
  • 88
    • 0036017044 scopus 로고    scopus 로고
    • Small cell lung carcinoma (SCLC): the angiogenic phenomenon
    • Lucchi M., Mussi A., Fontanini G., et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002, 21:1105-1110.
    • (2002) Eur J Cardiothorac Surg , vol.21 , pp. 1105-1110
    • Lucchi, M.1    Mussi, A.2    Fontanini, G.3
  • 89
    • 75149185856 scopus 로고    scopus 로고
    • Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a safety, feasibility, efficacy trial from the Hoosier oncology group
    • Jalal S.I., Bhatia S., Einhorn L.H., et al. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a safety, feasibility, efficacy trial from the Hoosier oncology group. ASCO Meeting Abs 2008, 26:19013.
    • (2008) ASCO Meeting Abs , vol.26 , pp. 19013
    • Jalal, S.I.1    Bhatia, S.2    Einhorn, L.H.3
  • 90
    • 49749108603 scopus 로고    scopus 로고
    • Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California consortium phase II study (NCI # 7097)
    • Ramalingam S.S., Mack P.C., Vokes E.E., et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California consortium phase II study (NCI # 7097). ASCO Meeting Abss 2008, 26:8078.
    • (2008) ASCO Meeting Abss , vol.26 , pp. 8078
    • Ramalingam, S.S.1    Mack, P.C.2    Vokes, E.E.3
  • 91
    • 49749137912 scopus 로고    scopus 로고
    • Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): a SWOG (S0435) phase II trial
    • Gitlitz B.J., Glisson B.S., Moon J., Reimers H., Gandara D.R. Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): a SWOG (S0435) phase II trial. ASCO Meeting Abs 2008, 26:8039.
    • (2008) ASCO Meeting Abs , vol.26 , pp. 8039
    • Gitlitz, B.J.1    Glisson, B.S.2    Moon, J.3    Reimers, H.4    Gandara, D.R.5
  • 92
    • 33644770041 scopus 로고    scopus 로고
    • Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier oncology group phase II trial
    • Moore A.M., Einhorn L.H., Estes D., et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier oncology group phase II trial. Lung Cancer 2006, 52:93-97.
    • (2006) Lung Cancer , vol.52 , pp. 93-97
    • Moore, A.M.1    Einhorn, L.H.2    Estes, D.3
  • 93
    • 75749130112 scopus 로고    scopus 로고
    • Phase II study of iressa (GEFITINIB) in relapsed and refractory small cell lung cancer (SCLC)
    • Langer S.W., Pedersen B.S., Ranson M., Pappot H., Loft A., Thatcher N. Phase II study of iressa (GEFITINIB) in relapsed and refractory small cell lung cancer (SCLC). J Thorac Oncol 2008, 3:S55.
    • (2008) J Thorac Oncol , vol.3
    • Langer, S.W.1    Pedersen, B.S.2    Ranson, M.3    Pappot, H.4    Loft, A.5    Thatcher, N.6
  • 94
    • 61449172019 scopus 로고    scopus 로고
    • Overview of gefitinib in non-small cell lung cancer: an Asian perspective
    • Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009, 39:137-150.
    • (2009) Jpn J Clin Oncol , vol.39 , pp. 137-150
    • Jiang, H.1
  • 95
    • 4444236880 scopus 로고    scopus 로고
    • Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer
    • Heymach J.V., Johnson D.H., Khuri F.R., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004, 15:1187-1193.
    • (2004) Ann Oncol , vol.15 , pp. 1187-1193
    • Heymach, J.V.1    Johnson, D.H.2    Khuri, F.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.